Clinical commissioning policy: infliximab for refractory sarcoidosis (excluding neurosarcoidosis)

Document first published:: 10 November 2023
Page updated:: 19 July 2024
Topic:: Specialised commissioning
Publication type:: Policy or strategy

Infliximab is recommended to be available off-label as a routine commissioning treatment option for refractory sarcoidosis (excluding neurosarcoidosis) within the criteria set out in this document.

Document

$Clinical commissioning policy: infliximab for refractory sarcoidosis (excluding neurosarcoidosis)$

Clinical commissioning policy: infliximab for refractory sarcoidosis (excluding neurosarcoidosis)

PDF
239 KB
10 pages

Document

$NHS England Evidence Review: Intravenous infusion of infliximab for refractory sarcoidosis (excluding neurosarcoidosis)$

NHS England Evidence Review: Intravenous infusion of infliximab for refractory sarcoidosis (excluding neurosarcoidosis)

PDF
965 KB

Document

$Evidence review: infliximab for refractory sarcoidosis (excluding neurosarcoidosis)$

Evidence review: infliximab for refractory sarcoidosis (excluding neurosarcoidosis)

PDF
293 KB

Document

$Clinical priorities advisory group: infliximab for refractory sarcoidosis (excluding neurosarcoidosis)$

Clinical priorities advisory group: infliximab for refractory sarcoidosis (excluding neurosarcoidosis)

PDF
280 KB

Document

$Clinical panel report January 2023: infliximab for refractory sarcoidosis (excluding neurosarcoidosis)$

Clinical panel report January 2023: infliximab for refractory sarcoidosis (excluding neurosarcoidosis)

PDF
236 KB

Document

$Clinical panel report June 2023: infliximab for refractory sarcoidosis (excluding neurosarcoidosis)$

Clinical panel report June 2023: infliximab for refractory sarcoidosis (excluding neurosarcoidosis)

PDF
131 KB

Document

$Engagement report: infliximab for refractory sarcoidosis (excluding neurosarcoidosis)$

Engagement report: infliximab for refractory sarcoidosis (excluding neurosarcoidosis)

PDF
154 KB

Document

$Equality and Health Inequalities Impact Assessment (EHIA): infliximab for refractory sarcoidosis (excluding neurosarcoidosis)$

Equality and Health Inequalities Impact Assessment (EHIA): infliximab for refractory sarcoidosis (excluding neurosarcoidosis)

PDF
192 KB

Cookies on the NHS England website